July 28, 2026 — Implicity has been granted U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its next-generation ILR ECG Analyzer. Implicity’s newly cleared ILR ECG algorithm can now analyze data from ICMs across all major device manufacturers, including Abbott, Biotronik, Boston Scientific, and Medtronic. FDA Clearance"Our vision is simple: AI should make expert cardiac care scalable without making it impersonal," said Arnaud Rosier, MD, PhD, CEO and co-founder of Implicity. Implicity’s next-generation ILR ECG Analyzer is expected to become commercially available to U.S. customers in the coming months. † - IM007 ILR ECG Analyzer is an FDA cleared Class II medical device, see the instructions for use for more information.